Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax in Mature B-Cell Malignancies
NCT04277637Phase 1Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Mar 2020
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 1, open-label trial of sonrotoclax in mature B-cell neoplasms, marginal zone lymphoma (MZL), follicular lymphoma (FL) and 5 more (6 arms), sponsored by BeOne Medicines. Primary endpoints: Treatment Emergent Adverse Events, Serious Adverse Events and 5 more. Started Mar 2020; status: active, not recruiting.
02
Drugs
sonrotoclax
03
Conditions
mature B-cell neoplasmsmarginal zone lymphoma (MZL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04277637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277637.